Research programme: TRPV1 cation channel antagonists - Amgen

Drug Profile

Research programme: TRPV1 cation channel antagonists - Amgen

Alternative Names: AMG 0347; AMG 2674; AMG 8163; AMG 9810; AMG8562; TRPV1 cation channel antagonists - Amgen

Latest Information Update: 08 Dec 2008

Price : $50

At a glance

  • Originator Amgen
  • Class Acrylamides; Pyridines; Small molecules
  • Mechanism of Action TRPV cation channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 07 Nov 2007 Adverse events data from a preclinical study presented at the 37th Annual Meeting of the Society for Neuroscience (SfN-2007)
  • 12 Jul 2006 A preclinical study have been added to the pharmacokinetics and pharmacodynamics sections
  • 07 Dec 2005 Data presented at the 35th Annual Meeting of the Society for Neuroscience (SfN-2005) have been added to the Pain pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top